ERCC4 and urinary bladder cancer: We found XPF was significantly less in tumor tissues of relapsed bladder cancer and the results from pathology comparison showed that the possibility of relapse within 3 years was higher for bladder cancer patients with XPF (−) than for those with XPF (+).